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Abstract
External guide sequences (EGSs) have successfully been used to inhibit expression of target genes at the post-
transcriptional level in both prokaryotes and eukaryotes. We previously reported that EGS accessible and cleavable sites in
the target RNAs can rapidly be identified by screening random EGS (rEGS) libraries. Here the method of screening rEGS
libraries and a partial RNase T1 digestion assay were used to identify sites accessible to EGSs in the mRNA of a global
virulence regulator MglB from Francisella tularensis, a Gram-negative pathogenic bacterium. Specific EGSs were
subsequently designed and their activities in terms of the cleavage of mglB mRNA by RNase P were tested in vitro and
in vivo. EGS73, EGS148, and EGS155 in both stem and M1 EGS constructs induced mglB mRNA cleavage in vitro. Expression
of stem EGS73 and EGS155 in Escherichia coli resulted in significant reduction of the mglB mRNA level coded for the F.
tularensis mglB gene inserted in those cells.
Citation: Xiao G, Lundblad EW, Izadjoo M, Altman S (2008) Inhibition of Expression in Escherichia coli of a Virulence Regulator MglB of Francisella tularensis Using
External Guide Sequence Technology. PLoS ONE 3(11): e3719. doi:10.1371/journal.pone.0003719
Editor: Yong-Sun Bahn, Yonsei University, Republic of Korea
Received September 19, 2008; Accepted October 24, 2008; Published November 13, 2008
Copyright:  2008 Xiao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Defense Threat Reduction Agency Grant W81XWH-06-2-0066, the Fulbright Foundation (E.W.L.), Research Council of
Norway grants (to E.W.L.), and Northern Norway Regional Health Authority Medical Research Program grants (to E.W.L.). The funders had no role in the study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sidney.altman@yale.edu
Introduction
Francisella tularensis is a Gram-negative, facultative intracellular
bacterium that is the etiological agent of tularemia [1]. Tularemia is
primarily a disease of the Northern hemisphere that is spread by
blood-sucking insects or acquired from contact with infected
animals such as rabbits or rodents. In addition, F. tularensis is a
category A agent of biowarfare/biodefense due to its high infectivity
and lethality when inhaled [2]. Survival and replication inside
macrophages of hosts is important for the virulence of F. tularensis.
The MglA and MglB proteins encoded in an operon regulate
transcription of a particular set of genes, some of which are required
for intramacrophage growth and virulence of F. tularensis [2–6].
Inhibition of gene expression at the RNA level has been
achieved by base-pairing EGSs with mRNAs of specific genes to
form a complex mimicking the natural substrates of RNase P [7–
11]. RNase P is a ubiquitous enzyme and its prime physiological
role is to cleave tRNA precursors (ptRNAs) to generate the 59
termini of mature tRNA molecules [12]. RNase P can specifically
cleave any RNA in vitro and in vivo, provided that the target RNA is
hybridized to an EGS that is complementary to the targeted
region [13,14]. EGSs have been designed to convert antimicrobial
resistance to sensitivity [8,11], inhibit bacterial viability, and
decrease secretion of virulence factors involved in host cell
invasion in Gram-negative bacteria [9,10].
In Escherichia coli, RNase P consists of M1 RNA and C5 protein.
The M1 RNA can execute the enzymatic function in vitro in the
absence of the C5 protein. Depending on whether or not M1 RNA
is covalently linked with an EGS, EGSs are classified as M1 EGSs
and stem EGSs, respectively.
Here we describe application of stem and M1 EGSs to induce F.
tularensis mglB mRNA cleavage by RNase P in E. coli. Stem and
M1 EGSs targeting positions 73, 148, and 155 cleaved the mglB
mRNA in vitro. Expression of stem EGSs targeting positions 73 and
155 resulted in a 50,60% reduction of the mglB mRNA level in
E. coli.
A similar successful method has been described to test EGSs on
different pathogens [15].
Results
Mapping in vitro of accessible sites in the mglB mRNA
Many RNAs spontaneously self-assemble into highly folded
structures. EGS accessible sites within target RNAs are determined
to facilitate the design of specific EGSs. Several methods have
been successfully used to identify accessible sites on various target
RNAs [16,17]. In this study, the rapid rEGS assay was used to
screen for stem EGSs that selectively cleave the target mglB
mRNA. An effective stem EGS candidate should meet the
following requirements: an EGS-directed cleavage reaction occurs
only if the target RNA is incubated with both rEGS and the
RNase P holoenzyme; the amount of cleavage product increases as
the amount of rEGS increases. Figure 1A suggests that an EGS
targets the position 155 (Fig. 1A and 1B).
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is guanine (G) in most cases. The rEGSs consisting of the random
14-nucleotide sequence (N14) and a cytosine (C) were designed to
bind to a G nucleotide in the target RNA. Interestingly the
nucleotide at position 155 in the mglB RNA is a C rather than a
G. In principle, the nucleotide next to the CACCA sequence in
rEGS(s) might be G, which base pairs with the nucleotide C at the
position 155 of the mglB sequence.
As described previously for screening rEGSs targeting the vjbR
mRNA of Brucella melitensis [17], both rEGSe and rEGSx libraries
were used (Fig. 1A). The only difference between rEGSe and
rEGSx is the shorter length of the 39 end of rEGSx mRNA that
resulted from the BstNI digestion of the DNA fragments for in vitro
transcription. Consistent with previous report (17), the rEGSx
library gave much stronger cleavage than the rEGSe library
(Fig. 1A).
The partial RNase T1 digestion assay is normally used to locate
the exposed G nucleotides in the target RNA [18]. The signal
strength of bands in the T1 lane in Figure 1A indicates the
accessibility of the G nucleotides in the mglB mRNA (Fig. 1A and
1B). Although not identified by the rEGS assay, positions 52, 73,
and 148 could be EGS accessible sites (Fig. 1A and 1B).
Cleavage in vitro of the mglB mRNA by specific EGSs
Stem EGSs and M1 EGSs targeting the potential cleavage sites,
52, 73, 148, and 155 (rEGS), were respectively made and tested in
cleavage assays in vitro. To follow the sequence of rEGSs,
N14CACCA, we designed EGS155R assuming the targeted
position 155 to be a G nucleotide. EGS155, which perfectly
base-pairs with the target mglB sequence, was also designed.
Figures 2A and 2B indicate that stem EGSs targeting positions 73,
148, and 155 were able to cleave the mglB mRNA. Increase of the
EGSs concentration resulted in increase of the amount of cleavage
products (Fig. 2A and 2B). Failure in base-pairing of the nucleotide
immediately next to ACCA in EGS155R with the target mglB
sequence resulted in loss of cleavage activity (Fig. 2B). The
cleavage sites were confirmed as shown in Figure 1A by 59 end-
labeling the mglB mRNA, cleavage assays in vitro, and then
separation by denaturing PAGE with alkali-treated mglB mRNA
and partial RNase T1 digested mglB mRNA as size markers (data
not shown).
Figures 3A and 3B show that higher concentration of Mg
2+
(100 mM) induced the M1 EGSs in the absence of RNase P
holoenzyme to give the same cleavage patterns as the correspond-
Figure 1. Mapping of accessible sites in the target mglB mRNA
by RNase T1 and rEGS libraries. A. Polyacrylamide gel electropho-
resis of cleavage products of 59end labeled mglB mRNA generated by
RNase P holoenzyme and rEGSe or rEGSx libraries. The RNase P
holoenzyme was reconstituted by 10 nM M1 RNA and 100 nM C5
protein. mglB mRNA cleavage products were separated on 8%
polyacrylamide/7 M urea gels together with an alkali ladder and a
partial RNase T1 digest of the same RNA. Arrows indicate positions
selected for further analyses. The black filled triangles represent
decreasing concentrations of rEGSs (1000-, 100-, and 10-fold molar
excess to the mglB mRNA) incubated with RNase P holoenzyme. Lane
OH represents the alkali ladder. Lanes T1 and M1+C5 represent reaction
with RNase T1 and RNase P holoenzyme, respectively. The difference
between rEGSe and rEGSx is the length of 39 end of rEGS mRNA resulted
from the BstNI digestion of the DNA fragments for in vitro transcription.
The numbers indicate the positions of cleavage relative to the mglB
translational initiation site. B. Complexes between the mglB mRNA and
EGS52, EGS73, EGS148, and EGS155. The secondary structure of the
partial mglB sequence used for the assay was created by the Mfold
program [21]. Signal strength is according to the RNase T1 assay.
doi:10.1371/journal.pone.0003719.g001
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(Fig. 2A, 2B, 3A, and 3B). Consistent with the results of stem
EGSs, only M1 EGSs targeting positions 73, 148, and 155 cleaved
the mglB mRNA. Increase of the M1 EGSs concentration resulted
in increase of the amount of cleavage products (Fig. 3A and 3B).
M1 EGS52 and M1 EGS155R could not cleave the mglB mRNA
(Fig. 3B and data not shown).
Specific EGSs induce reduction of the mglB mRNA level
in E. coli
To confirm if EGS73, EGS148, and EGS155 induce reduction
of the mglB mRNA level in vivo, we transcribed the mglB gene and
the stem EGSs from the same plasmid in E. coli by creating the
plasmids pMlac-mglB-EGS73, pMlac-mglB-EGS148, pMlac-
mglB-EGS155, pMlac-mglB-M1EGS73, pMlac-mglB-
M1EGS148, and pMlac-mglB-M1EGS155.
Transcription of mglB was under the control of the rnpB
promoter and transcription of EGSs under the control of the
IPTG-inducible T7 promoter (data not shown). To avoid the
mutual influence of the two promoters, mglB and EGSs were
transcribed in opposite directions. Figures 4A and 4B show that
IPTG-induced expression of stem EGS73 and EGS155 resulted in
reduction of the mglB mRNA level to 40,50% of that without the
EGSs in E. coli cells. Surprisingly, the mglB mRNA level increased
in the presence of leaky expression of stem EGS148 for unknown
reasons but increase of EGS148 transcription still resulted in
reduction of the mglB mRNA level (Fig. 4A and 4B). None of the
Figure 2. Cleavage in vitro of the mglB mRNA by the RNase P
holoenzyme in the absence or presence of stem EGSs. A.
Activities of stem EGS155 and EGS155R. B. Activities of stem EGS52,
EGS73, and EGS148. If needed, 10 nM M1 RNA and 100 nM C5 protein in
buffer PA were added to reconstitute the RNase P holoenzyme. The
mglB mRNA cleavage products were separated on 8% polyacrylamide/
7 M urea gels along with the mglB mRNA alone or the mglB mRNA with
the RNase P holoenzyme. Internally labeled pSupS1 ptRNA was used as
a positive control to check for activity of the reconstituted RNase P
holoenzyme. EGSs were added in 100-, 50-, and 10-fold molar excess to
the mglB mRNA, denoted by black triangles.
doi:10.1371/journal.pone.0003719.g002
Figure 3. Cleavage in vitro of the mglB mRNA by the M1 EGSs
alone in the presence of high MgCl2 concentration. A. Activities
of M1 EGS155. B. Activities of M1 EGS52, M1 EGS73, and M1 EGS148.
The RNase P holoenzyme was reconstituted by 10 nM M1 RNA and 100
nM C5 protein. If M1 EGS or M1 RNA was added in the absence of the
C5 protein, additional 90 mM MgCl2 was added. The mglB mRNA
cleavage products were separated on 8% polyacrylamide/7 M urea gels
together with the mglB mRNA alone or the mglB mRNA with M1 and/or
C5 components of the RNase P holoenzyme. Internally labeled pSupS1
ptRNA was used as a positive control to check for activity of the
reconstituted RNase P holoenzyme or M1 RNA alone in the presence of
high MgCl2 concentration. Stem EGS155 and M1 EGSs (M1 EGS52, M1
EGS73, M1 EGS148, or M1 EGS155) were added in 10-, 50- or 100-fold
molar excess to mglB mRNA, denoted by black triangles.
doi:10.1371/journal.pone.0003719.g003
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reduction of the mglB mRNA level in E. coli (data not shown) as
shown previously for other M1 EGSs in E. coli (C. Guerrier-
Takada, Yale University, unpublished data).
Discussion
We successfully identified two EGSs, EGS73 and EGS155,
which induced reduction of the mRNA level of the global
virulence regulator MglB from F. tularensis both in vitro and in E.
coli. In a previous report, stem EGS117 and EGS166 were
identified to cleave the mRNA of a virulence regulator VjbR from
B. melitensis in vitro [17]. We subsequently found that stem EGS117
reduced the vjbR mRNA level in E. coli by 80% and stem EGS166
by 100% compared with that in the absence of the two EGSs (data
not shown). Thus, it is possible that if the EGSs, EGS73 and
EGS155 for mglB of F. tularensis and EGS117 and EGS166 for
vjbR of B. melitensis, are delivered to the pathogenic bacteria, they
will reduce their target mRNA levels so that virulence of the
bacteria will be reduced.
The method of screening rEGS libraries has successfully been used
to identify accessible and cleavable sites in the target RNA [17]. All
specific EGSs that we have designed so far based on the results of the
rEGS method are able to cleave the target mRNAs [17]. The
efficiency of the rEGS method is better than that of any other method
that has been used, including the partial RNase T1 digestion assay.
However, in some cases where we searched for rEGS, we have been
unable to identify any EGS-induced cleavable site or EGS accessible
sites that were identified by other methods [15,17]. There are two
ways to solve the problem. One is to combine the results of the rapid
rEGS method and the partial RNase T1 digestion assay to design
specific EGSs, as we did in this study. The other is to make a
transcript of the target gene that is much larger than the one used in
this case sothat the whole landscape of the targeted gene is examined.
The nucleotide G is preferred to lie immediately next to the
natural ptRNA cleavage site and base-pairs with the nucleotide C
before the ACCA sequence in the 39 end of the ptRNA cleavage
product [17]. When we originally designed the rEGS libraries, we
used the nucleotide C after the N14 sequence and before the ACCA
sequence to base-pair with the nucleotide G in target RNAs [17].
Interestingly, the nucleotide C at the position 155 of the mglB
sequence identified by the rEGS method does not follow this rule.
However, difference in base-pairing of a single nucleotide in
EGS155 and EGS155R with the nucleotide G significantly affects
EGS-induced RNase P cleavage activity (Fig. 2A), suggesting the
importance of base-pairing between EGSs and the nucleotide next
to the cleavage site. The interaction between the nucleotide T at the
position 156 of the mglB sequence and the nucleotide A next to the
CACCAsequence inEGS155R maybe tooweak to form a mRNA-
EGS complex to induce RNase P cleavage activity.
While we have outlined a safe method to test the effect of EGSs
on genes from pathogenic bacteria in this report, we also note that
shuttle plasmids that contain the successful EGSs have been
constructed and are now in the process of being tested in the actual
pathogens in BL3 facilities of the Armed Forces Insitute of
Pathology. The efficiency of EGS inactivation of expression of
target genes can be enhanced by putting two EGSs attacking
different siteson thetarget mRNA ona shuttle plasmid. Indeed, two
EGSs attacking the same site can also be used. Agents that can be
injected into mice or administered to them by nasal inhalation will
be used in these experiments. Chemically modified EGSs that can
be taken up by bacteria (Avi Biopharma, Corvallis, Oregon) should
be used in this respect and might be successful. Clinical application
of these EGSs will rely on the results of the mouse experiments.
Materials and Methods
Materials
Oligonucleotides were made by the Yale synthesis facility (New
Haven, CT). Restriction endonucleases, DNA polymerase I
Klenow fragment, T4 polynucleotide kinase, and T4 DNA ligase
were purchased from New England Biolabs (Cambridge, MA).
SP6 and T7 RNA polymerases were purchased from Promega
(Madison, WI). Qiaquick PCR purification kit, Qiaquick gel
extraction kit, and Qiaprep spin miniprep kit were purchased from
Qiagen (Chatsworth, CA). AmpliTaq DNA polymerase was
purchased from Roche (Indianapolis, IN). Ultrafree-MC column
was purchased from Millipore (Billerica, MA). [a-
32P]GTP and
[c-
32P]ATP were purchased from Amersham (Piscataway, NJ) and
PerkinElmer (Boston, MA).
Strains and growth conditions
Bacterial strains used are listed in Table 1. E. coli cells were
grown at 37uC in Luria-Bertani (LB) broth or on LB agar. E. coli
Figure 4. Analysis of stem and M1 EGSs activity in vivo. A.
Northern analysis of the mglB mRNA level in E. coli. The plasmid vector
pKB283-Mlac without (2) mglB nor (2) EGS was used as a negative
control. The plasmid vector pMlac-mglB with (+) mglB but without (2)
EGS was used as a positive control. The plasmids pMlac-mglB-EGS73,
pMlac-mglB-EGS148, and pMlac-mglB-EGS155 carried both (+) mglB and
EGS73, EGS148, and EGS155, respectively. Total RNAs were prepared
from E. coli BL21(DE3) cells in the absence (2) or presence (+) of IPTG to
induce expression of the EGSs listed. The RNA samples were separated
on 2% agarose gels. The mglB mRNA was probed with 59 end labeled
oligonucleotide RNA155 and the 5S rRNA with 5S1 on the same
membrane. The experiments were independently done twice and only
a typical figure was shown. B. Average of the relative mglB mRNA level
in E. coli. The ratios of the mglB mRNA to the 5S rRNA for cells carrying
different plasmids were calculated. The ratio for cells carrying pMlac-
mglB was chosen as 100% to calculate the relative mglB mRNA level in
other cells listed.
doi:10.1371/journal.pone.0003719.g004
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E. coli BL21(DE3) was used for protein expression. Ampicillin or
carbenicillin (100 mg/ml) was used for plasmid selection and
maintenance in E. coli.
Preparation of the target mglB mRNA
Restricted genomic DNA of F. tularensis was obtained from the
Armed Forced Institute of Pathology, Washington, DC. The
template for the mglB mRNA of F. tularensis was prepared as
described previously [17]. To map accessible sites in the mglB
mRNA, the 59 fragment was amplified by PCR using primers
mglB F (59- ATGGCTATGCTTAGAGCATATG-39) and mglB
R( 5 9- TCATCATCTTCGCCTTCATT-39). The PCR fragment
was sub-cloned into the pGEM-T vector, generating the plasmid
pGEMglB. To reduce the length of the vector sequence between
the T7 promoter in the pGEM-T vector and the inserted DNA
fragment, the plasmid pGEMglB was digested with the restriction
enzymes ApaI and SacII, purified from an agarose gel using
Ultrafree-MC columns, blunt ended using DNA polymerase I
Klenow fragment, and then re-ligated using T4 DNA ligase. The
resulting plasmid pGEDMglB was digested with the restriction
enzymes FokI and TaqI, ethanol-precipitated and dissolved in
distilled water, and used as the template for in vitro transcription
using T7 RNA polymerase [17]. For internally labeled transcripts,
[a-
32P]GTP was used during the transcription reaction. For the
mapping of cleavage sites, transcripts were labeled at the 59 end
using [c-
32P]ATP and T4 polynucleotide kinase.
Mapping of accessible sites in the mglB mRNA
The rEGS assay for the mglB mRNA was performed as
described previously [17]. Partial RNase T1 reaction was
performed as previously described (8). After the reaction, the
Table 1. Bacterial strains and plasmids.
Strains/Plasmids Relevant characteristics References/Source
Strains
DH5a F
2 w80dlacZDM15 D(lacZYA-argF)U169 deoR recA1 endA1
hsdR17(rk
2 mk
+) phoA supE44 l





2) gal dcm l(DE3) Novagen
Plasmids
pGEM-T Cloning vector; Amp
r Promega
pGEMglB pGEM-T with mglB PCR product; Amp
r This study
pGEDMglB pGEMglB with ApaI-SacII deletion; Amp
r This study
pSupS1 pSP64 with tRNA
ser insert; Amp
r [22]
pUCT7/AEFRNAHHT7T pUC19-derived cloning vector with T7 promoter and terminator,
and HH sequence; Amp
r
Guerrier-Takada C, unpublished
pUCT7mglBEGS52 pUCT7/AEFRNAHHT7T with stem EGS52 PstI-BstEII insert; Amp
r This study
pUCT7mglBEGS73 pUCT7/AEFRNAHHT7T with stem EGS73 PstI-BstEII insert; Amp
r This study
pUCT7mglBEGS148 pUCT7/AEFRNAHHT7T with stem EGS148 PstI-BstEII insert; Amp
r This study
pUCT7mglBEGS155 pUCT7/AEFRNAHHT7T with stem EGS155 PstI-BstEII insert; Amp
r This study
pUCT7mglBEGS155R pUCT7/AEFRNAHHT7T with stem EGS155R PstI-BstEII insert; Amp
r This study




pUCT7M1mglBEGS52 pUCT7/M1AEFRNAHHT7T with stem EGS52 PstI-BstEII insert; Amp
r This study
pUCT7M1mglBEGS73 pUCT7/M1AEFRNAHHT7T with stem EGS73 PstI-BstEII insert; Amp
r This study
pUCT7M1mglBEGS148 pUCT7/M1AEFRNAHHT7T with stem EGS148 PstI-BstEII insert; Amp
r This study
pUCT7M1mglBEGS155 pUCT7/M1AEFRNAHHT7T with stem EGS155 PstI-BstEII insert; Amp
r This study
pUCT7M1mglBEGS155R pUCT7/M1AEFRNAHHT7T with stem EGS155R PstI-BstEII insert; Amp
r This study
pKB28359HHC5EGS139HHM1T pUC19-derived cloning vector pKB283 with 59HHC5EGS139HH insert; Amp
r [18]
pKB283-mglB pKB283 with mglB BamHI-BstEII insert; Amp
r This study
pMlac pUC19 with a mutated lacZ promoter; Amp
r [15]
pMlac-mglB pKB283-mglB with a mutated lacZ promoter; Amp
r This study
pKB283-Mlac pKB28359HHC5EGS139HHM1T with a mutated lacZ promoter; Amp
r This study
pMlac-mglB-EGS73 pMlac-mglB with stem EGS73 HindIII-EcoRI insert; Amp
r This study
pMlac-mglB-EGS148 pMlac-mglB with stem EGS148 HindIII-EcoRI insert; Amp
r This study
pMlac-mglB-EGS155 pMlac-mglB with stem EGS155 HindIII-EcoRI insert; Amp
r This study
pMlac-mglB-M1EGS73 pMlac-mglB with M1 EGS73 HindIII-EcoRI insert; Amp
r This study
pMlac-mglB-M1EGS148 pMlac-mglB with M1 EGS148 HindIII-EcoRI insert; Amp
r This study
pMlac-mglB-M1EGS155 pMlac-mglB with M1 EGS155 HindIII-EcoRI insert; Amp
r This study
Amp
r, ampicillin resistant; HH, hammerhead.
doi:10.1371/journal.pone.0003719.t001
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that contained 7 M urea. Partial alkaline ladder digests were
carried out as previously described [17]. Cleavage sites were
determined by comparing rEGS-mediated and partial RNase T1
cleavage products to partial alkaline ladder results. The yeast
suppressor precursor tRNA
Ser (SupS1) was internally labeled with
[a-
32P]GTP and used as a substrate in control reaction [15,19].
Preparation of stem and M1 EGSs against the mglB
mRNA
Specific EGSs were designed based on the rEGS assay and partial
RNase T1 assay according to previous reports [17,18]. The specific
EGSs used for in vitro cleavage assays were phosphorylated at their 59
ends, annealed together by heating at 95uC for 5 min and cooled
down slowly. The annealed oligos had the restriction enzymes PstI
and BstEII overhangs at the 59 and 39 ends, respectively. These oligos
used for EGS52, EGS73, EGS148, EGS155, and EGS155R were 52
(59- GTGTAAATCCATGATCACCAG-39), 52 compl (59-
GTGACCTGGTGATCATGGATTTACACTGCA-39), 73 (59-
GAGTATCAACTAAAACACCAG-39), 73 compl (59-G T G A C -
CTGGTGTTTTAGTTGATACTCTGCA-39), 148 (59- GTTGA-
GGAGATAAATCACCAG-39),1 4 8c o m p l( 5 9- GTGACCTGGT-
GATTTATCTCCTCAACTGCA-39), 155 (59- GGTATTGCTT-
GAGGAGACCAG-39), 155 compl (59- GTGACCTGGTCTCCT-
CAAGCAATACCTGCA-39), 155R (59- GGTATTGCTT-
GAGGACACCAG-39), 155R compl (59- GTGACCTGGT-
GTCCTCAAGCAATACCTGCA-39). The hybridized EGS oligos
were inserted into a pUC19-based vector containing the T7
promoter, pUCT7/AEFRNAHHT7T, pre-digested with PstIa n d
BstEII, generating the plasmids pUCT7mglBEGS52, pUCT7mgl-
BEGS73, pUCT7mglBEGS148, pUCT7mglBEGS155, and
pUCT7mglBEGS155R. To create the templates for M1 EGSs, the
hybridized EGS oligos were inserted into a pUC19-based vector
containing the T7 promoter and an M1, pUCT7/M1AEFR-
NAHHT7T, pre-digested with PstIa n dBstEII, generating the
plasmids pUCT7M1mglBEGS52, pUCT7M1mglBEGS73,
pUCT7M1mglBEGS148, pUCT7M1mglBEGS155, and
pUCT7M1mglBEGS155R. These constructs were sequenced and
the plasmids digested with BstEII, ethanol-precipitated and dissolved
in distilled water, and used as templates for in vitro transcription.
EGS activity assays in vitro
EGS activity assays were performed according to a previous
report [17]. The EGS in 100-, 50- or 10-fold molar excess was
incubated with 10 nM of 59 end-labeled or internally labeled target
mRNAs in PA buffer (50 mM Tris-Cl, pH 7.5, 10 mM MgCl2,
100 mM NH4Cl) for 5 min at room temperature. Subsequently,
10 nM of M1 RNA and 100 nM of C5 protein were added to the
mixture and further incubated for 30 min at 37uC. For reactions
with M1 or M1 EGS RNA alone, 100 nM of M1 or M1 EGS
RNA was used in PA100 buffer (PA buffer containing 100 mM
MgCl2). Reactions in 10 ml volume were performed at 37uC for
30 min, and terminated by adding 10 ml of 10 M urea/10%
phenol solution. The product was separated on 5% polyacryl-
amide that contained 7 M urea gels.
Construction of plasmids for the EGS activity assay in E.
coli
The plasmids contain the platform expressing both a target
mRNA and a specific EGS by using the rnpB promoter for the
target mglB mRNA and the T7 promoter for various EGSs. An
additional ‘C’ was introduced into the -35 region of lacZ on the
plasmids in order to inactivate transcription from the lacZ
promoter by making a StuI site [15].
The full-length mglB gene was amplified by PCR using primers
mglBtot F (59- CAGGATCCAAAAGGAGCTTAATATGGC-
TATG-39) and mglBtot R (59- CACAGGTGACCGAAT-
TAATCTAACGAAAGAACG-39), containing restriction sites
for BamHI and BstEII, respectively. The PCR products was
digested with BamHI and BstEII, purified from agarose gel using
Ultrafree-MC columns, and cloned into a pUC19-based plasmid
vector, pKB28359HHC5EGS139HHM1T, digested with the same
restriction enzymes, generating the plasmid pKB283-mglB.
To make the mutagenesis in the -35 region of lacZ in the
plasmids, the HindIII-AflIII fragment, which carries the mutated
lacZ promoter, from the plasmid pMlac was cut and inserted into
the plasmid pKB283-mglB to create pMlac-mglB. The HindIII-
AflIII fragment was also inserted into the plasmid
pKB28359HHC5EGS139HHM1T to create pKB283-Mlac.
The HindIII-EcoRI fragments from the plasmids pUCT7mgl-
BEGS73, pUCT7mglBEGS148, pUCT7mglBEGS155,
pUCT7M1mglBEGS73, pUCT7M1mglBEGS148, and
pUCT7M1mglBEGS155 were blunt-ended with the Klenow
fragment and inserted into the pMlac-mglB plasmid which was cut
with EcoRI, and then blunt-ended with the Klenow fragment. The
resultant plasmids were named pMlac-mglB-EGS73, pMlac-mglB-
EGS148, pMlac-mglB-EGS155, pMlac-mglB-M1EGS73, pMlac-
mglB-M1EGS148, and pMlac-mglB-M1EGS155.
Northern analysis
Freshly transformed cells were used for Northern analysis.
BL21(DE3) competent cells (150 ml) were mixed with 0.1 mg of the
appropriate plasmid and transformed at 42uC for 90 sec. The
transformed cells were cultured overnight at 37uC on an LB plate
with ampicillin. It is essential to use freshly transformed cells: when
the cells were cultured from the glycerol stock of transformed cells,
the expression of EGS was poor very often. A colony was picked
from the LB plate and was cultured overnight in LB media
containing carbenicillin at 37uC.
The overnight culture was diluted 1:100 and incubated at 37uC
to OD600=0.6. The cells were split into two tubes and 2 mM
(final concentration) IPTG was added into one of the tubes. The
cells were further incubated for one hour and total RNA was
prepared as described previously [20]. The RNAs (4 mg) were
separated on a 2% agarose gel.
Northern blot analysis was performed as described previously
[7]. Oligonucleotides of RNA155 (59-CTT GTA TTG CTT GAG
GAG ATA AAT CT-39), 73 compl, 148 compl, 155 compl, and
5S1 (59-TAC CAT CGG CGC TAC GGC GTT TCA CTT C-
39) were labeled at their 59 ends using [c-
32P]ATP and then used
as probes for mglB mRNA, EGS73, EGS148, EGS155, and 5S
rRNA, respectively.
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